Buys | $4,955,728 | 1 | 13 |
Sells | $11,061,140 | 7 | 87 |
Chambers Michael Andrew | director | 1 | $4.96M | 0 | $0 | $4.96M |
Boor Kathryn Jean | director | 0 | $0 | 1 | $205,400 | $-205,400 |
Murray Dallan | Chief Customer Officer | 0 | $0 | 1 | $508,900 | $-508,900 |
Estepan Ian Michael | Chief Financial Officer | 0 | $0 | 1 | $822,100 | $-822,100 |
Wigzell Hans Lennart Rudolf | director | 0 | $0 | 1 | $1.31M | $-1.31M |
Arif Bilal | Chief Tech Ops Officer | 0 | $0 | 2 | $1.92M | $-1.92M |
Brown Ryan Edward | EVP, General Counsel | 0 | $0 | 1 | $6.3M | $-6.3M |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 …
Over the last 12 months, insiders at Sarepta Therapeutics, Inc. have bought $4.96M and sold $11.06M worth of Sarepta Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sarepta Therapeutics, Inc. have bought $6.22M and sold $11.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Chambers Michael Andrew (director) — $4.96M.
The last purchase of 37,038 shares for transaction amount of $4.96M was made by Chambers Michael Andrew (director) on 2024‑08‑16.
2024-12-12 | Sale | Wigzell Hans Lennart Rudolf | director | 10,500 0.011% | $124.84 | $1.31M | -6.99% | |
2024-12-05 | Sale | Boor Kathryn Jean | director | 1,636 0.0017% | $125.55 | $205,400 | -7.51% | |
2024-08-30 | Sale | Estepan Ian Michael | Chief Financial Officer | 5,985 0.0063% | $137.36 | $822,100 | -10.44% | |
2024-08-16 | Chambers Michael Andrew | director | 37,038 0.0404% | $133.80 | $4.96M | -7.99% | ||
2024-06-25 | Sale | Arif Bilal | Chief Tech Ops Officer | 3,898 0.0043% | $163.23 | $636,271 | -20.99% | |
2024-06-25 | Sale | Brown Ryan Edward | EVP, General Counsel | 38,957 0.0421% | $161.61 | $6.3M | -20.99% | |
2024-06-24 | Sale | Arif Bilal | Chief Tech Ops Officer | 7,859 0.0083% | $163.08 | $1.28M | -23.74% | |
2024-05-02 | Sale | Murray Dallan | Chief Customer Officer | 3,635 0.0041% | $140.00 | $508,900 | -4.30% | |
2024-03-11 | Sale | Boor Kathryn Jean | director | 761 0.0008% | $122.93 | $93,550 | +3.09% | |
2024-03-08 | Sale | Wigzell Hans Lennart Rudolf | director | 15,000 0.0159% | $123.25 | $1.85M | +0.78% | |
2024-03-05 | Sale | Mayo Stephen | director | 3,135 0.0033% | $122.96 | $385,480 | +2.03% | |
2024-03-01 | Sale | Estepan Ian Michael | Chief Financial Officer | 1,200 0.0013% | $128.30 | $153,960 | -2.59% | |
2024-03-01 | Sale | Brown Ryan Edward | EVP, General Counsel | 2,000 0.0021% | $125.34 | $250,680 | -2.59% | |
2024-03-01 | Sale | Arif Bilal | Chief Tech Ops Officer | 2,000 0.0021% | $128.84 | $257,676 | -2.59% | |
2023-11-03 | INGRAM DOUGLAS S | President & CEO | 25,225 0.0275% | $79.36 | $2M | +60.46% | ||
2023-11-03 | Barry Richard | director | 50,000 0.0542% | $78.81 | $3.94M | +60.46% | ||
2023-08-14 | Chambers Michael Andrew | director | 9,979 0.0104% | $109.47 | $1.09M | +7.99% | ||
2023-08-11 | Chambers Michael Andrew | director | 23,686 0.0254% | $108.05 | $2.56M | +12.24% | ||
2023-08-10 | Chambers Michael Andrew | director | 34,867 0.0374% | $106.15 | $3.7M | +14.36% | ||
2023-08-04 | Sale | Wigzell Hans Lennart Rudolf | director | 15,000 0.0163% | $106.72 | $1.6M | +14.59% |
Chambers Michael Andrew | director | 284034 0.2927% | $27.94M | 5 | 0 | +11.57% |
HAYWOOD GEORGE WEAVER | 8213717 8.4649% | $807.98M | 16 | 0 | <0.0001% | |
INGRAM DOUGLAS S | President & CEO | 390307 0.4022% | $38.39M | 7 | 0 | +25.87% |
Barry Richard | director | 140000 0.1443% | $13.77M | 7 | 3 | +30.38% |
BEHRENS M KATHLEEN | director | 130517 0.1345% | $12.84M | 6 | 2 | +42.52% |
$961,890,236 | 276 | 22.46% | $13.1B | |
$211,610,344 | 91 | 38.45% | $7.13B | |
$2,765,836 | 72 | 20.00% | $13.47B | |
$108,876,545 | 67 | 72.81% | $7.52B | |
Sarepta Therapeutics, Inc. (SRPT) | $42,463,802 | 57 | 17.85% | $9.55B |
Increased Positions | 235 | +45.19% | 10M | +11.11% |
Decreased Positions | 223 | -42.88% | 7M | -8.46% |
New Positions | 74 | New | 3M | New |
Sold Out Positions | 60 | Sold Out | 2M | Sold Out |
Total Postitions | 532 | +2.31% | 89M | +2.65% |
Blackrock, Inc. | $1.19M | 11.66% | 11.19M | +168,672 | +1.53% | 2024-12-31 |
Vanguard Group Inc | $969,872.00 | 9.46% | 9.09M | +117,904 | +1.31% | 2024-12-31 |
Capital International Investors | $928,419.00 | 9.06% | 8.7M | +2M | +38.95% | 2024-12-31 |
Janus Henderson Group Plc | $462,048.00 | 4.51% | 4.33M | -30,188 | -0.69% | 2024-12-31 |
State Street Corp | $434,458.00 | 4.24% | 4.07M | -200,902 | -4.7% | 2024-12-31 |
Farallon Capital Management Llc | $305,849.00 | 2.98% | 2.87M | +285,100 | +11.05% | 2024-12-31 |
Avoro Capital Advisors Llc | $272,805.00 | 2.66% | 2.56M | 0 | 0% | 2024-12-31 |
Bank Of New York Mellon Corp | $229,030.00 | 2.24% | 2.15M | +26,581 | +1.25% | 2024-12-31 |
Wellington Management Group Llp | $220,841.00 | 2.16% | 2.07M | -657,842 | -24.13% | 2024-12-31 |
Jpmorgan Chase & Co | $215,699.00 | 2.11% | 2.02M | -178,279 | -8.11% | 2024-12-31 |